English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer

Kandra, P., Nandigama, R., Eul, B., Huber, M., Kobold, S., Seeger, W., et al. (2022). Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. FRONTIERS IN IMMUNOLOGY, 13: 903562. doi:10.3389/fimmu.2022.903562.

Item is

Basic

show hide
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Kandra, Prameela, Author
Nandigama, Rajender1, Author           
Eul, Bastian, Author
Huber, Magdalena, Author
Kobold, Sebastian, Author
Seeger, Werner1, Author           
Grimminger, Friedrich, Author
Savai, Rajkumar1, Author           
Affiliations:
1Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Max Planck Society, ou_2591698              

Content

show
hide
Free keywords: -
 Abstract: The present treatments for lung cancer include surgical resection, radiation, chemotherapy, targeted therapy, and immunotherapy. Despite advances in therapies, the prognosis of lung cancer has not been substantially improved in recent years. Chimeric antigen receptor (CAR)-T cell immunotherapy has attracted growing interest in the treatment of various malignancies. Despite CAR-T cell therapy emerging as a novel potential therapeutic option with promising results in refractory and relapsed leukemia, many challenges limit its therapeutic efficacy in solid tumors including lung cancer. In this landscape, studies have identified several obstacles to the effective use of CAR-T cell therapy including antigen heterogeneity, the immunosuppressive tumor microenvironment, and tumor penetration by CAR-T cells. Here, we review CAR-T cell design; present the results of CAR-T cell therapies in preclinical and clinical studies in lung cancer; describe existing challenges and toxicities; and discuss strategies to improve therapeutic efficacy of CAR-T cells.

Details

show
hide
Language(s):
 Dates: 2022-06-02
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 000811908900001
DOI: 10.3389/fimmu.2022.903562
PMID: 35720364
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: FRONTIERS IN IMMUNOLOGY
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 13 Sequence Number: 903562 Start / End Page: - Identifier: ISSN: 1664-3224